Larimar Therapeutics, Inc. (LRMR)
Develops experimental medicines for rare genetic diseases using peptide technology.
$3.83+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+11.3%
The outlook
LRMR is trading near the lower end of its 52-week range, with analysts overwhelmingly favoring the stock at Strong Buy consensus. The average analyst price target sits roughly 276% above the current price, though the stock's recent price action has been mixed against its moving averages.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 10 analysts
Price trendMixed vs its moving averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +276% vs current price
Analyst price target
~12-month · 10 analysts$14.40average target+276.0% vs now
Now $3.83
Low $5.00High $26.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$397.9M
52-wk high
$6.42
52-wk low
$2.72
50-day avg
$3.56
200-day avg
$3.92
Trailing P/E
—